Momenta Pharmaceuticals, Inc.

Industry

  • Biotechnology
    • Drug Discovery Technologies
    • Large Molecule
      • Antibodies
  • Pharmaceuticals

Other Names/Subsidiaries

  • Mimeon, Inc.
See more in Biomedtracker

Latest on Momenta Pharmaceuticals, Inc.

Scrip

J&J Interested In ‘Differentiated’ Obesity Assets

 
• By Jessica Merrill

Johnson & Johnson is not ruling out being a late entrant into the obesity space. During an appearance at the Morgan Stanley Healthcare Conference on 4 September, CEO Joaquin Duato said the company is

Scrip

J&J In Immunology: 'We Plan To Lead The Orals Market'

 
• By Jessica Merrill

With a long strong heritage in immunology on the strength of blockbuster brands like Remicade (infliximab), Stelara (ustekinumab) and Tremfya (guselkumab), Johnson & Johnson is looking to continue i

Pink Sheet

Biosimilar Antibody-Drug Conjugates? Pfizer Isn’t Banking On It

 
• By Dean Rudge

Pfizer Inc. ’s recent determination to pay $43bn for antibody-drug conjugate (ADC) pioneer Seagen Inc. , the largest pharmaceutical deal since AbbVie Inc. ’s $63bn takeover of Allergan plc three y

In Vivo

Seagen Deal Ticks The Big Three For Pfizer: Revenues, Pipeline, Platform

 
• By Scrip Team

Pfizer Inc. agreed to pay $43bn in cash for antibody-drug conjugate (ADC) developer Seagen Inc. earlier this month. The US pharma giant said Seagen’s four approved products – three ADCs and a small